Introduction
Myelodysplastic syndromes (MDS) include a heterogeneous group of acquired clonal stem-cell disorders. The FrenchAmerican-British (FAB) group has classified MDS in five groups: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-t) and chronic myelomonocytic leukemia (CMML). 1 The clinical course of MDS varies from a quiescent form to a rapidly fatal disease depending on several prognostic factors. 2 The International Prognostic Scoring System (IPSS) can be used as a model to estimate survival and the likelihood of leukemic transformation. 3 As the majority of patients with MDS and secondary acute myeloid leukemia (sAML) are elderly, the most frequent therapy is supportive care. 4 Intensive chemotherapy is usually limited to the 25% of patients o60 years. Complete remission (CR) rates between 15 and 64% have been reported. [5] [6] [7] [8] [9] [10] [11] Remission duration, however, is short due to a high relapse rate. The most effective curative treatment is allogeneic hematopoietic cell transplantation (HCT). Factors predicting a better outcome such as younger age and early stage of disease have been identified. 12 Best results have been obtained using HLA-identical siblings. Published results indicate that at least one-third of patients are cured of their disease. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Unfortunately, most patients do not have HLA-identical siblings. Alternative donors include nonidentical family members 28, 29 or matched unrelated donors (MUD). 22, 23, [30] [31] [32] [33] Autologous HCT is also increasingly used with encouraging results. 28, [34] [35] [36] [37] This retrospective study conducted by the MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT) compared the outcome of patients with MDS/sAML lacking an HLA-matched sibling who received either autologous or allogeneic HCT from MUD.
Patients and methods
The CLWP of the EBMT has collected data on 593 consecutive patients with MDS/sAML who received an autologous or allogeneic HCT from MUD from 1991 to 2003. Allogeneic HCT from MUD without prior chemotherapy (MUD-U) was performed in 167 (28%) patients. The rest received HCT in CR1 after induction chemotherapy (Autologous (Auto-CR1), n ¼ 290 (49%) and allogeneic HCT from MUD (MUD-CR1), n ¼ 136 (23%)). Induction chemotherapy to achieve CR1 consisted of one to two cycles of AML-like chemotherapy according to the AML protocol of each center. MDS was classified according to the criteria of the FAB working group. 1 Because of intercenter variability in evaluating cytogenetics, the IPSS score was not applied in the present analysis. Primary MDS as well as therapyrelated MDS defined as MDS occurring after exposure to cytotoxic or immunosuppressive treatment for nonrelated conditions were included. Patients with sAML defined as AML (4 30% blasts in the bone marrow) developing after preexisting MDS with a duration of at least 3 months or after chemotherapy or radiotherapy for nonrelated disease were also included.
Patient characteristics
Median age was 40 (range 18-65) years. A total of 111 (19%) patients were o20, while 288 (49%) were 440 years old. Diagnoses were RA/RARS, n ¼ 78 (13%), RAEB, n ¼ 100 (17%), RAEB-t, n ¼ 101 (17%) and sAML, n ¼ 314 (53%). Median interval between diagnosis and HCT was 6 (range 0-180) months. Recipients of an autologous HCT were older than recipients of an allogeneic HCT (Po0.001). In the Auto-CR1 group, 189 (65%) patients were 440 years, while only 99 (33%) patients 440 years received an allogeneic HCT. RAEB-t and sAML were present in 253 (87%) and 119 (88%) patients in Auto-CR1 and MUD-CR1 groups, respectively. Only 43 (10%) of 415 patients with RAEB-t and sAML received HCT from MUD without prior chemotherapy, while 68 of 78 (87%) patients with RA/RARS received MUD-U. Data on conditioning regimens were available in 549 patients. A total of 508 (93%) patients received HCT after standard myeloablative regimens consisting of cyclophosphamide and/or busulfan with or without totalbody irradiation (TBI). Only 9 (8%) and 32 (22%) patients in MUD-CR1 and MUD-U received HCT after various reduced intensity conditionings (RIC), respectively. Patient-, disease-and treatment-related characteristics are summarized in Table 1 .
End points
Primary end points were overall survival (OS), disease-free survival (DFS), transplantation-related mortality (TRM), and relapse incidence (RI). Duration of survival was calculated from HCT to death, from whatever cause. Patients were censored if alive at the time of last follow-up. Relapse or death was the event for DFS. Patients were censored if relapse free and alive at time of last follow-up. Death without relapse was the event for TRM. Relapse was the event for the estimation of RI. Patients were either censored if relapse free and alive at time of last follow-up or at time of death without relapse.
Statistical analysis
Survival curves were computed using the Kaplan-Meier technique with date of HCT as starting point. 38 In all multivariable analyses, the following covariates were used: age, stage of disease and interval diagnosis-HCT. The log rank test or the associated trend test was used for comparison of Kaplan-Meier curves. 39 Potential prognostic factors for outcome were evaluated in multivariable analyses using Cox proportional hazards regression. 40 Variables considered were type of HCT: Auto-CR1 vs MUD-CR1 vs MUD-U, age: o20 vs 20-40 vs 440 years, diagnosis: RA/RARS vs RAEB vs RAEB-t vs sAML and interval diagnosis-HCT: o6 vs 6-12 vs 412 months.
As most deaths occurred within the first 6 months after HCT (MUD-U (88%), MUD-CR1 (74%), Auto-CR1 (67%)), this time point was used as a landmark to analyze whether the influence of various variables on outcome at 3 years was proportional and constant over time after HCT.
To study whether the influence of the type of HCT on outcome was age dependent or not, we generated Cox models with three patterns corresponding to patients o20, 20-40 and 440 years. To eliminate the influence of disease status on outcome, only patients with sAML (n ¼ 314) were included in the Cox models of this analysis.
Results
End points at 3 years Overall survival. Median OS was 19 months (95% CI, 10-27). MUD-U had the shortest median OS time of 9 (95% CI, 4-15) compared to 33 (95% CI, 0-81) for MUD-CR1 and 22 months (95% CI, 13-32) for Auto-CR1. OS for all patients was 42%. Survival was best in MUD-CR1 (50%) compared to Auto-CR1 (41%) and MUD-U (40%) (P ¼ 0.01) (Figure 1a) . In univariable analysis, 6-12 months between diagnosis and HCT was associated with the best median survival time of 33 (95% CI, 15-51) compared to 17 (95% CI, 11-23) and 8 months (95% CI, 4-12) for patients transplanted o6, and 412 months after diagnosis, respectively. TBI in the conditioning regimen had no effect on OS. In multivariable analysis, the type of HCT again influenced OS. MUD-U had the highest relative death rate (hazard ratio (HR) 2.3 (95% CI, 1.6-3.3)) compared to Auto-CR1 (44) 53 (39) 148 (51) Age (years) o20 41 (24) 53 (39) 17 (6) 20-40 63 (38) 47 (35) 84 (29) 440 63 (38) 36 (26) 189 (65) FAB subtype RA/RARS 68 (41) 6 (4) 4 (1) RAEB 56 (33) 11 (8) 33 (11) RAEB-t 26 (16) 27 (20) 48 (17) sAML 17 (10) 92 (68) 205 (71) Interval diagnosis-HCT (months) o6 43 (26) 55 (40) 131 (45) 6-12 62 (37) 62 (46) 127 (44) 412 62 (37) 19 (14) 32 (11) Total body irradiation in the conditioning regimen Abbreviations: Auto-CR1, autologous HCT in first complete remission after induction chemotherapy; FAB, French-American-British; HCT, hematopoietic cell transplantation; MDS, myelodysplasia; MUD-U, allogeneic HCT from matched unrelated donor without prior chemotherapy (untreated); MUD-CR1, allogeneic HCT from matched unrelated donor in first complete remission after induction chemotherapy; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ringed sideroblasts; sAML, secondary acute myeloid leukemia.
( Table 2 ). Stage of disease at HCT was found to be another important factor. Survival of patients with RA/RARS was better (HR 0.4 (95% CI, 0.3-0.7)) compared to patients with more advanced disease. HCT performed 6-12 months after diagnosis was associated with the highest (HR 0.7 (95% CI, 0.6-1.0)) and HCT 4 12 months after diagnosis with the lowest (HR 1.3 (95% Type of HCT *** *** *** * ** Auto-CR1
(1)
Interval diagnosis-HCT *** *** ** * o6
( Abbreviations: Auto-CR1, autologous HCT in first complete remission after induction chemotherapy; DFS, disease-free survival; HCT, hematopoietic cell transplantation; MDS, myelodysplasia; MUD-U, allogeneic HCT from matched unrelated donor without prior chemotherapy (untreated); MUD-CR1, allogeneic HCT from matched unrelated donor in first complete remission after induction chemotherapy; RA, refractory anemia; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; RARS, RA with ring sideroblasts; OS, overall survival; sAML, secondary acute myeloid leukemia. *Po0.05; **Po0.01; ***Po0.001.
CI, 1.0-1.9)) survival compared to HCT performed o6 months. Survival in patients 20-40 and 440 years was not significantly lower compared to patients o20 years (Table 2) .
Disease-free survival. MUD-CR1 had the best median DFS time of 19 (95% CI, 0-38) compared to 5 (95% CI, 3-7) and 10 (95% CI, 8-11) months for MUD-U and Auto-CR1, respectively. DFS for the entire cohort was 33%. DFS was lowest in Auto-CR1 (28%) and highest in MUD-CR1 (44%) (P ¼ 0.03) (Figure 1b) . Again, 6-12 months between diagnosis and HCT was associated with the best median DFS time of 11 (95% CI, 6-16) compared to 8 (95% CI, 5-11) and 5 (95% CI, 3-7) months for patients transplanted o6, and 412 months after diagnosis, respectively. TBI in the conditioning regimen had no effect on DFS. In multivariable analysis, the type of HCT influenced DFS. MUD-U had the lowest (HR 1.4 (95% CI, 1.0-2.0)) and MUD-CR1 the highest (HR 0.8 (95% CI, 0.6-1.1)) DFS compared to Auto-CR1. Other prognostic factors that predicted a better DFS were RA/ RARS, and 6-12 months between diagnosis and HCT. Similar to OS, DFS was not significantly different in the three age groups (Table 2) .
Transplantation-related mortality. TRM for the entire cohort was 31%. TRM was significantly higher after allogeneic HCT (MUD-U (49%), MUD-CR1 (38%)) compared to 17% in Auto-CR1 (Po0.001) (Figure 1c ). It was higher in patients who received TBI (P ¼ 0.007). Patients transplanted 412 months after diagnosis had a significantly higher TRM compared to patients transplanted 6-12 months after diagnosis (Po0.001). In multivariable analysis, the type of HCT significantly affected TRM being highest in MUD-U (HR 7.4 (95% CI, 4.3-12.8))
compared to Auto-CR1. TRM after HCT for RA/RARS was lowest (HR 0.4 (95% CI, 0.2-0.8)) compared to sAML. Also, HCT 6-12 months after diagnosis was associated with the lowest TRM. Interestingly, TRM in patients 20-40 (HR 1.6 (95% CI, 1.0.2.6)) and 440 years (HR 1.5 (95% CI, 1.0.2.5)) was not significantly higher compared to patients o20 years (Table 3 ).
Relapse incidence. RI for the entire cohort was 48%. RI in Auto-CR1 (62%) was significantly higher compared to allogeneic HCT (MUD-U (30%), MUD-CR1 (24%)) (Po0.001) (Figure 1d ). RI was lower for RA/RARS compared to other disease groups (Po0.001). TBI had no effect on RI. In multivariable analysis, only the type of HCT was a significant factor with RI being lowest after allogeneic HCT (HR for MUD-CR1 0.3 (95% CI, 0.2-0.5) and for MUD-U 0.3 (95% CI, 0.2-0.6)) compared to Auto-CR1 (Table 3) .
Landmark analysis
Recipient of allogeneic HCT had a high risk of death in the first 6 months only (HR for MUD-U 4.9 (95% CI, 2.9-8), for MUD-CR1 2.4 (95% CI, 1.5-3.9)) compared to Auto-CR1. However, for patients surviving these months, survival in MUD-CR1 (HR 0.5 (95% CI, 0.3-0.9)) was actually superior to Auto-CR1. The same is true for disease stage and interval between diagnosis and HCT. The better OS at 3 years for RA/RARS compared to more advanced disease, and if HCT was performed 6-12 months after diagnosis compared to HCT 412 months after diagnosis, was mainly due to the impact of these factors on OS in the first 6 months. Age was not statistically significant for OS at any time ( Table 2) . Interval diagnosis-HCT (months) *** *** * o6
(1) The impact of the prognostic factors on DFS showed a similar pattern to that described for OS regarding type of HCT, stage of disease and interval between diagnosis and HCT. Interestingly, DFS in the first 6 months for all age groups was similar. Beyond this time, DFS for patients 440 years was inferior (HR 2.3 (95% CI 1-4.7)) compared to patients o20 years ( Table 2 ).The higher TRM at 3 years after allogeneic HCT compared to Auto-CR1 was mainly due to the high TRM in the first 6 months (HR for MUD-U 9.7 (95% CI, 5.2-18), for MUD-CR1 4.6 (95% CI, 2.5-8.4)) compared to Auto-CR1. For patients surviving this time, TRM after allogeneic HCT was still higher compared to Auto-CR1, but not statistically significant (P ¼ 0.5). The impact of the stage of disease and interval between diagnosis and HCT on TRM at 3 years was mainly due to the influence of these factors in the first 6 months, while age remained constantly not significant over time (Table 3) . On the other hand, RI was significantly higher in auto-CR1 compared to allogeneic HCT at all time points after HCT ( Table 3) .
Influence of age and type of HCT on outcome at 3 years in patients with sAML OS and DFS in Auto-CR1 were age dependent. Outcome worsened proportionally with increasing age. Similarly, OS and DFS in MUD-U were strongly age dependent with best outcome in patients o20 years. For patients 20-40 and 440 years, outcome was worst in MUD-U. On the other hand, survival and DFS in MUD-CR1 were not age dependent. For patients 20-40 and 440 years, DFS was best in MUD-CR1 followed by Auto-CR1. Regarding TRM and RI, the type of HCT and not age as shown previously for all disease stages was crucial (Figure 2 ).
Discussion
In this retrospective analysis, although comparison with other published data is difficult because of different patient characteristics, outcome after allogeneic HCT from MUD was similar to known results of HCT from related sibling donors. The estimated 3 year DFS in a study of the IBMTR as well as in an analysis of the EBMT were 40 and 36%, respectively for patients transplanted from an HLA-identical sibling donor. 25, 26 In a recent retrospective study conducted by the EBMT regarding HCT in patients with MDS 50 years or older, the outcome of 1000 matched sibling and 385 MUD transplants were compared. Donor type did not influence the 4-year TRM (HR 1. Our data do not favor allogeneic HCT without induction chemotherapy for patients 420 years with overt leukemia. There is debate regarding whether there is advantage in giving chemotherapy to achieve remission before HCT. The Seattle group did not find a significant difference between treated and untreated patients and favor HCT without induction chemotherapy, even in patients with overt leukemia. 22, 41 In other transplantation series, a low neoplastic cell burden is one of the most relevant factors influencing outcome. 25, 26, 28, 35 In our retrospective analysis, a selection bias for patients who were fit enough to receive and survive intensive chemotherapy followed by HCT in CR1 from MUD might have been introduced. Prospective randomized trials and/or studies on an intention-totreat basis are two possibilities to compare the outcome of the two approaches.
TRM remains high for both MUD-U and MUD-CR1. This is similar to TRM observed in other series. 17, 19, 20, 23, 24, 28, 30, 41 The influence of TBI is still a matter of debate. In our series, TRM was significantly higher if TBI was given as part of the conditioning regimen. This is in accordance with published data where patients whose preparative regimen did not contain TBI had a better outcome. 42 Autologous HCT may be an alternative treatment option for patients without an identical sibling donor. 28, [34] [35] [36] [37] Our analysis assessed a large number of patients in Auto-CR1. The majority suffered from RAEB-t and sAML. Survival and DFS were lower for this patient cohort compared to recipients of HCT from MUD. Nevertheless, several aspects need to be addressed. First, the low TRM after autologous HCT is counterbalanced by a high RI but long-term DFS is possible. Second, a primary prerequisite for autologous HCT is the induction of a CR with sufficient numbers of normal stem cells available for harvesting. In a prospective study of the EORTC, EBMT, SAKK and GIMEMA leukemia groups comparing the outcome of patients with highrisk MDS/sAML treated with intensive chemotherapy followed by HCT on an intention-to-treat basis a significantly higher number of patients received the intended allogeneic compared to autologous HCT. 27 Third, the impact of bad prognostic cytogenetic features on RI after autologous HCT remains to be assessed. Fourth, recipients of autologous HCT were significantly older compared to those who received allogeneic HCT. This implies that clinicians prefer allogeneic for younger and autologous HCT for older patients. To date, the choice between MUD-HCT or autologous HCT is ambiguous. For the entire cohort, older age had no significant negative impact on outcome after HCT. Interestingly, in our age-dependent analysis for patients with sAML, patients 440 years did as well as patients Autologous and unrelated donor HCL in MDS and secondary AML HK Al-Ali et al between 20 and 40 years with OS and DFS being best for MUD-CR1 followed by Auto-CR1. These data imply that older age may not automatically be associated with a negative impact on outcome after allogeneic HCT. However, these data must be interpreted with caution as the number of patients 440 years who received an allogeneic HCT was relatively small. Two aspects might aid physicians in decision-making and defining goals of treatment. First, the landmark analysis which is not a predictor of survival at HCT but showed that apart from relapse in Auto-CR1 that continued to be a constant risk factor over time, the influence of the type of HCT, stage of the disease and the interval between diagnosis and HCT on long-term outcome at 3 years was not proportional nor constant over time and mainly due to the impact these factors had in the first 6 months after HCT. For example, survival at 3 years in MUD-CR1 was statistically not different from that seen after Auto-CR1. But at 6 months after HCT, survival in MUD-CR1 was inferior, mainly due to TRM, compared to Auto-CR1. However, for patients surviving these first 6 months, survival in MUD-CR1 was better than Auto-CR1 mainly due to the continued risk of relapse-related mortality after autologous HCT. Second, the data available on the impact of age and type of HCT on outcome. For example, for patients o20 years with sAML, OS and DFS at 3 years after autologous HCT were 60 and 28%, respectively, while OS and DFS after allogeneic HCT without prior induction chemotherapy were 40%. This implies that if this patient would survive HCT, DFS at 3 years, and possibly cure, would be more likely after allogeneic HCT. On the other hand, for a patient 440 years, physicians may prefer autologous HCT despite the high RI to avoid the high TRM after allogeneic HCT.
The optimal timing of HCT for MDS with its variable natural history is still not well defined. In our analysis, outcome for all types of HCT was best if HCT was performed 6-12 months after diagnosis. This likely reflects patient and disease features as frequent blood transfusions, longer pancytopenias and possibly progression to more advanced disease before HCTs may be reasons explaining the lower OS and higher TRM in patients transplanted more than 12 months after diagnosis. The availability of new-non-transplant modalities as the DNA hypomethylating compounds azacytidine and decitabine may further affect the timing and outcome of HCT. [43] [44] [45] In our series, no patient received HCT after treatment with one of the novel agents. Decision analysis such as the Markov decision model published by Cutler et al. 46 where patient risk-assessment data were performed for all IPSS risk groups may aid medical decision-making regarding the optimal time of HCT.
Finally, age of patients eligible for conventional HCT is not representative of the overall population with MDS. Although results have improved progressively over the last years, TRM and RI remain high after allogeneic and autologous HCT, respectively. A variety of RIC regimens have been developed in the last years which may offer a potential alternative to patients with advanced age or comorbidities and substantially reduce TRM. [47] [48] [49] [50] [51] The impact of the intensity of the conditioning regimen on the outcome after HCT was addressed in a recent retrospective analysis of the EBMT in patients with MDS 50 years or older were the outcome of HCT after RIC and myeloablative conditioning were compared. RIC was associated with a lower TRM (HR 0.7 (95% CI, 0.57-0.88) (Po0.01)) but a higher RI (HR 1.5 (95% CI, 1.2-1.9) (Po0.001)) compared to myeloablative conditioning so that the 4-year OS was comparable in the two groups (Lim ZY et al. Blood 2006, 108: 157a, abstract). Prospective randomized studies, which are currently underway, may aid in clarifying patient selection criteria and identifying optimal conditioning strategies in patients with MDS.
